Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting

Journal of Medical Economics
Cibele SuzukiSiew Hwa Ong

Abstract

Omalizumab add-on to standard-of-care therapy has proven to be efficacious in severe asthma patients for whom exacerbations cannot be controlled otherwise. Moreover, evidence from different healthcare settings suggests reduced healthcare resource utilization with omalizumab. Based on these findings, this study aimed to assess the cost-effectiveness of the addition of omalizumab to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. A previously published Markov model was adapted using Brazil-specific unit costs to compare the costs and outcomes of the addition of omalizumab to standard-of-care therapy vs standard-of-care therapy alone. Model inputs were largely based on the eXpeRience study. Costs and health outcomes were calculated for lifetime-years and were annually discounted at 5%. Both one-way and probabilistic sensitivity analyses were performed. An additional cost of R$280,400 for 5.20 additional quality-adjusted life-years was estimated with the addition of omalizumab to standard-of-care therapy, resulting in an incremental cost-effectiveness ratio of R$53,890. One-way sensitivity analysis indicated that discount rates, standard-of-care therapy exacerbation r...Continue Reading

References

Dec 22, 1998·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·S C ToughJ C Butt
Apr 15, 1999·Resuscitation·O LöwhagenM Rosenfeldt
Aug 19, 2005·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·G G AlvarezJ M Fitzgerald
May 23, 2006·Respiratory Medicine·Stephen P PetersColin Reisner
Aug 18, 2006·Respiratory Medicine·Mary K MillerUNKNOWN TENOR Study Group
Feb 14, 2007·Primary Care Respiratory Journal : Journal of the General Practice Airways Group·Andrew LloydRuth Brown
Jul 27, 2007·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·L A SantosA L G Fernandes
Oct 2, 2007·The Journal of Allergy and Clinical Immunology·Ann C WuAnne L Fuhlbrigge
Mar 18, 2011·The New England Journal of Medicine·William W BusseChristine A Sorkness
May 4, 2011·Annals of Internal Medicine·Nicola A HananiaWilliam Busse
Feb 24, 2012·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·A S RubinUNKNOWN QUALITX Study Investigators
Sep 8, 2012·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Roberto Walter Dal NegroLorenzo Pradelli
Dec 12, 2012·Journal of Medical Economics·Floortje van NootenRuth E Brown
Nov 14, 2013·The World Allergy Organization Journal·Eduardo CostaRogerio Rufino
Jul 6, 2014·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Alberto Nahon LevyMaría Victoria Hidalgo Sanjuan
Sep 12, 2014·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Andréia Guedes Oliva FernandesAlvaro Augusto Cruz
Nov 6, 2014·Biologics in Therapy·Gert-Jan BraunstahlPanayiotis Georgiou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.